These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 91856)
41. Levodopa in the treatment of Parkinson's disease: current controversies. Gerlach M; Reichmann H; Riederer P Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130 [No Abstract] [Full Text] [Related]
42. A combined regimen of subcutaneous lisuride and oral Madopar HBS in Parkinson's disease. Chouza C; Caamaño JL; de Medina O; Aljanati R; Scaramelli A; Romero S J Neural Transm Suppl; 1988; 27():61-70. PubMed ID: 3042913 [TBL] [Abstract][Full Text] [Related]
43. The use of pergolide, a potent dopamine agonist, in Parkinson's disease. Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733 [TBL] [Abstract][Full Text] [Related]
44. Use of ergot derivative lisuride in Parkinson's disease. Suchy I; Horowski R Adv Neurol; 1984; 40():515-21. PubMed ID: 6695629 [No Abstract] [Full Text] [Related]
45. Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease. Capria A; Attanasio A; Quatrana M; Cannata D; Fioravanti M; Stocchi F; Ruggieri S Clin Neuropharmacol; 1989 Aug; 12(4):331-8. PubMed ID: 2804995 [TBL] [Abstract][Full Text] [Related]
46. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Lera G; Vaamonde J; Muruzabal J; Obeso JA Ann Neurol; 1990 Oct; 28(4):593-4. PubMed ID: 2252377 [No Abstract] [Full Text] [Related]
47. Use of lisuride in advanced Parkinson's disease. Potent dopamine and serotonin agonist. Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Goodgold A; Pact V; Walker R N Y State J Med; 1981 Nov; 81(12):1751-5. PubMed ID: 6949052 [No Abstract] [Full Text] [Related]
48. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Stocchi F; Ruggieri S; Vacca L; Olanow CW Brain; 2002 Sep; 125(Pt 9):2058-66. PubMed ID: 12183351 [TBL] [Abstract][Full Text] [Related]
50. Lisuride in the treatment of Parkinsonism. Schachter M; Sheehy MP; Parkes JD; Marsden CD Acta Neurol Scand; 1980 Dec; 62(6):382-5. PubMed ID: 7468157 [TBL] [Abstract][Full Text] [Related]
51. Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease. Obeso JA; Luquin MR; Martínez Lage JM Ann Neurol; 1986 Jan; 19(1):31-5. PubMed ID: 3947037 [TBL] [Abstract][Full Text] [Related]
52. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. Allain H; Destée A; Petit H; Patay M; Schück S; Bentué-Ferrer D; Le Cavorzin P Eur Neurol; 2000; 44(1):22-30. PubMed ID: 10894991 [TBL] [Abstract][Full Text] [Related]
53. Comparison between L-dopa and lisuride intravenous infusions: a clinical study. Ruggieri S; Stocchi F; Carta A; Bravi D; Bragoni M; Giorgi L; Agnoli A Mov Disord; 1988; 3(4):313-9. PubMed ID: 3211176 [TBL] [Abstract][Full Text] [Related]
57. [Lisuride in the combination treatment of Parkinson disease]. Jellinger K Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099 [TBL] [Abstract][Full Text] [Related]
58. Intravenous lisuride infusion for Parkinson's disease. Obeso JA; Martinez-Lage JM; Luquin MR; Bolio N Ann Neurol; 1983 Aug; 14(2):252. PubMed ID: 6625541 [No Abstract] [Full Text] [Related]
59. Chronic s.c. lisuride in Parkinson's disease--motor-performance and avoidance of psychiatric side effects. Bittkau S; Przuntek H J Neural Transm Suppl; 1988; 27():35-54. PubMed ID: 3165438 [TBL] [Abstract][Full Text] [Related]